Evaluation of the protective effect of Curcuma Longa induced nephrotoxicity in patients with cancer

Not Applicable

Recruiting

• Conditions: Cisplatin induced nephrotoxicity.; Acute kidney failure, unspecified; N17.9

• Registration Number: IRCT20151228025732N70
• Lead Sponsor: Semnan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 January 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Age 18-60 years
Confirmation of cancer by a specialist doctor
The disease should be such that the use of cisplatin as a treatment is approved by a specialist doctor

Exclusion Criteria

The patient has a previous kidney disease (GFR is low from the beginning)
Existence of underlying diseases such as diabetes, hypertension, etc. in the patient
Increased creatinine indicated for discontinuation of the drug

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Blood creatinine level. Timepoint: Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin. Method of measurement: Biorexfars Laboratory Diagnostic Kit.;BUN(Blood Urea Nitrogen) level. Timepoint: Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin. Method of measurement: Biorexfars Laboratory Diagnostic Kit.;Creatinine Clearance level. Timepoint: Before starting treatment with Cisplatin and 5 and 21 days after starting treatment with Cisplatin. Method of measurement: Through Up-to-date software and using the CKD-EPI formula.